KLM LABS PVT announced today that the FDA has approved its ANDA220017 for the targeted substance, marking a potential expansion of its product portfolio. The clearance is expected to be significantly accretive to earnings by 2026 as the firm gains entry into a key market segment with the newly authorized generic formulation.